TO SHAREHOLDERS
Dear Shareholders,
Rs Indian pharmaceutical companies have emerged as some of the most
competitive players in the RsB ever-evolving generic drug space, building an unmatched
platform of global relevance. These companies are making their presence felt across
emerging markets worldwide, particularly with W strong portfolios in anti-infective and
anti-retroviral drugs. Large domestic pharma firms continue to grow, assuming leadership
positions in numerous therapies and segments within the Indian market, while also building
a robust international export backbone. They are now expanding into Tier II cities and
rural regions, helping make medical care more accessible to a broader segment of the
Indian population.
The United States has imposed a sweeping 10% tariff on all imported
goods, along ¦itev with additional country-specific duties, as part of broader
efforts to shift global trade dynamics and promote domestic manufacturing.
While pharmaceutical imports are RsRsRsB currently exempt from the
steeper reciprocal tariffs, the industry RsRsRsB remains vulnerable to the wider
RsRsRsB economic consequences of this new
RsRsRsB trade policy. The exact impact on
RsRsRsB pharmaceutical companies is difficult to determine, given the
vast and complex manufacturing networks that span multiple geographies and involve
numerous suppliers.
Even if finished drugs are not directly subjected to higher tariffs,
increased costs for imported raw materials could still disrupt manufacturing and raise
prices. If pharmaceuticals are added to the list of tariffed goods in the future, the
sector may face rising production costs, supply chain disruptions, and higher drug prices
for consumers. These pressures could also extend into the clinical trial supply chain,
potentially making the US a less attractive destination for business operations.
In this evolving landscape, the Company has strategically positioned
itself to capitalize on opportunities while remaining committed to sustainability. Our
focus on research and development, coupled with our expertise in complex chemistries, has
enabled us to deliver innovative, environmentally friendly solutions that meet growing
global demand.
It gives me great pride to report that the Company continues to excel
in its efforts to distinguish itself in the industry. As the Sudarshan Family, we are
driven by a strategic focus on differentiation and a commitment to execution at scale with
uncompromising quality. Our strategy always prioritizes quality over quantity.
We intend to expand our activities further through:
Ishwari Healthcare, which specializes in providing superior,
user-friendly, and state-of-the-art healthcare disposables and devices that conform to
international standards at competitive prices.
Sudarshan Maven, which focuses on the manufacturing of APIs,
intermediates, and pharmaceutical products.
With the support of these subsidiaries, Sudarshan Family aims to set
new benchmarks in the years ahead.
We are also taking the necessary steps to commence operations at our
DSIR-approved R&D and F&D Centre in Dehradun. This facility will focus on the
formulation development of innovative molecules in oral, liquid, and injectable dosage
forms.
We extend our deepest gratitude to our employees, customers, and
shareholders for their unwavering support. I personally thank everyone who has been a part
of the Sudarshan Family's incredible journey. Your continued support has been instrumental
to our success, and we are honored to have you with us.
We look forward to connecting with you again.
Regards,
Hemal Mehta
Founder, Chairman & Managing Director